50 Results for "

Splicing activity

" in MedChemExpress (MCE) Product Catalog:
Products (50)

50 Results for "Splicing activity" in MCE Product Catalog:

Cat. No.: HY-147412D
Target:  

Fluorescent Dye

Research Areas:  

Neurological Disease

FAM labled Ultevursen sodiumis a FAM labled Ultevursen sodium (HY-147412A). Ultevursen sodium (QR-421a) is a splice-modulating antisense oligonucleotide targeting exon 13 of the USH2A gene, which restores the functional expression of Usherin protein by inducing exon skipping. Ultevursen sodium binds to USH2A pre-mRNA and modulates the splicing process to specifically skip exon 13 carrying the pathogenic mutation c.2299delG, generating an in-frame transcript and a truncated yet functionally normal protein. Ultevursen sodium exhibits concentration-dependent exon skipping activity in human cells and retinal organoid models, and restores Usherin expression and retinal function in zebrafish and gene-edited mouse models. Ultevursen sodium can be used for related research on type 2 Usher syndrome and non-syndromic retinitis pigmentosa .
loading...
    loading...
Cat. No.: HY-147412E
Target:  

Fluorescent Dye

Research Areas:  

Neurological Disease

Cy3 labled Ultevursen sodium is a Cy3 labled Ultevursen sodium (HY-147412A). Ultevursen sodium (QR-421a) is a splice-modulating antisense oligonucleotide targeting exon 13 of the USH2A gene, which restores the functional expression of Usherin protein by inducing exon skipping. Ultevursen sodium binds to USH2A pre-mRNA and modulates the splicing process to specifically skip exon 13 carrying the pathogenic mutation c.2299delG, generating an in-frame transcript and a truncated yet functionally normal protein. Ultevursen sodium exhibits concentration-dependent exon skipping activity in human cells and retinal organoid models, and restores Usherin expression and retinal function in zebrafish and gene-edited mouse models. Ultevursen sodium can be used for related research on type 2 Usher syndrome and non-syndromic retinitis pigmentosa .
loading...
    loading...
Cat. No.: HY-114461A
CAS No.: 1228183-92-3
Target:  

Drug Derivative

Research Areas:  

Cancer

(16R,17S)-FD-895, a similar compound to FD-895 (HY-114461), is a potent in vivo splice regulatory agent. (16R,17S)-FD-895 retains the similar anti-proliferative activity as FD-895. (16R,17S)-FD-895 can be used for research on colon cancer .
loading...
    loading...
Cat. No.: HY-177972
Zotadirsen is the core component of the AOC drug Delpacibart zotadirsen (AOC1044) (HY-177564), consisting of a phosphorodiamidate morpholino oligonucleotide (PMO) targeting exon 44 of the dystrophin gene and an SMCC linker (HY-42360). Upon conjugation with the anti-TfR1 antibody Delpacibart (HY-P990051), Zotadirsen exerts splicing regulatory activity and mediates exon skipping. Zotadirsen can be used in studies related to AOC synthesis .
loading...
    loading...
Cat. No.: HY-171808
CAS No.: 2798907-16-9
Research Areas:  

Cancer

ITRI-90 is an orally effective androgen receptor (AR) PROTAC degrader. ITRI-90 effectively degrades full-length AR (AR-FL) and its splice variant AR-V7 proteins via the ubiquitin-proteasome system, thereby inhibiting AR transcriptional activity and the expression of its target genes, and further inducing tumor cell apoptosis. ITRI-90 can be used in research related to castration-resistant prostate cancer and Enzalutamide (HY-70002)-resistant prostate cancer .
loading...
    loading...
Cat. No.: HY-W1058476
CAS No.: 1443367-20-1
Target:  

GPR35 GPR55 Arrestin

Research Areas:  

Inflammation/Immunology Cancer

GPR35 agonist 6 is a potent and selective agonist targeting GPR35, with an EC50 of 12.1 nM against human GPR35. GPR35 agonist 6 activates the human splice variant GPR35b with comparable efficacy, showing an EC50 of 22.1 nM. GPR35 agonist 6 also exhibits weak GPR55 antagonistic activity, with an IC50 of 21.7 μM, and its agonistic activity towards GPR35 is significantly stronger than its antagonistic activity towards GPR55. GPR35 agonist 6 initiates GPR35 downstream signaling by inducing β-arrestin recruitment. GPR35 agonist 6 is used to investigate GPR35-mediated diseases, such as gastrointestinal lesions and gastric cancer .
loading...
    loading...
Cat. No.: HY-187172
CAS No.: 2060801-74-1
Target:  

hnRNP

Research Areas:  

Neurological Disease

BDF34019555 is a blood-brain barrier-permeable binder targeting the conserved region (amino acid residues 320-340) of TDP-43, with a Kd of 10.4 μM for full-length TDP-43 and 7.8 μM for the CR polypeptide, respectively. BDF34019555 binds to the conserved α-helical region of TDP-43 in a Trp334-dependent manner, inhibits liquid-liquid phase separation, aggregation and mitochondrial localization of TDP-43, restores mitochondrial function, reduces cytoplasmic and insoluble TDP-43 levels, without affecting the splicing activity of TDP-43. BDF34019555 exerts neuroprotective effects, alleviates motor neuron loss and improves motor neuron function. BDF34019555 can be used in studies related to amyotrophic lateral sclerosis .
loading...
    loading...
Cat. No.: HY-P11698
CAS No.: 476667-31-9
Research Areas:  

Cancer

Guanidino-G-Clamp-PNA is a highly efficient sequence-specific RNA binder and gene silencer. Guanidino-G-Clamp-PNA precisely targets such targets as miR-155 or transthyretin (TTR) mRNA through base pairing: the former regulates tumor-related signaling pathways by reducing microRNA activity, while the latter inhibits the translation of harmful proteins via steric hindrance. Guanidino-G-Clamp-PNA effectively stabilizes DNA/RNA duplexes, induces cancer cell apoptosis, and suppresses tumor growth. In addition, Guanidino-G-Clamp-PNA can be conjugated with targeting ligands to improve tissue-specific delivery and reduce in vivo adverse reactions, and it can also enhance the splicing regulation efficacy of other oligonucleotide platforms (such as PMO) when integrated into them. Guanidino-G-Clamp-PNA is applicable to the research of various diseases including diffuse large B-cell lymphoma and hereditary transthyretin-related amyloidosis .
loading...
    loading...
Cat. No.: HY-L248
858 compounds

The RNA-targeted bioactive compound library is a high-quality collection of small molecules specifically designed and curated to target RNA structures and functions. It is widely applied in cutting-edge drug discovery and life science research. Unlike traditional strategies that focus on protein targets, RNA-targeted compounds can directly modulate various functional RNA molecules by influencing their splicing, translation, stability, or structural conformation, thereby enabling precise intervention in key biological processes. In the field of drug development, these compounds provide a novel approach to addressing previously “undruggable” targets and have demonstrated significant potential in areas such as oncology, antiviral therapies, and neurodegenerative diseases. For example, by targeting disease-associated RNA structural domains or regulating the aberrant expression of non-coding RNAs, these compounds can effectively inhibit disease progression or restore normal cellular function. In mechanistic studies, RNA-targeted compounds serve as valuable chemical biology tools to elucidate the roles of RNA in gene expression regulation, cellular signaling pathways, and disease development.

The MCE RNA-targeted bioactive compound library contains 858 compounds, sourced from databases such as TargetRX Atlas and R-BIND. The library features excellent structural diversity and biological activity, making it suitable for high-throughput screening (HTS), target validation, phenotypic screening, and lead compound discovery. It represents a valuable resource for RNA-related research and innovative drug development.

Cat. No.: HY-123996
CAS No.: 20041-64-9
3-Ethoxy-5,6-dibromosalicylaldehyde is an IRE1/ERN1 inhibitor, with an IC50 of 0.12 μM, a Ki of 71-88 nM, and a Kd of 100 nM against the ribonuclease activity of hIRE1α, as well as an IC50 of 4.8 μM against yeast Ire1. It shows selectivity toward IRE1 ribonuclease. 3-Ethoxy-5,6-dibromosalicylaldehyde blocks the IRE1/ERN1-mediated unfolded protein response (UPR) signaling pathway, including XBP-1 mRNA splicing, induction of XBP1 target genes, and activation of MAPK8/9/10, but does not alter the phosphorylation level of IRE1α or the PERK/ATF6 pathway. 3-Ethoxy-5,6-dibromosalicylaldehyde inhibits chikungunya virus replication, induces growth arrest, apoptosis and clonogenic inhibition in pancreatic cancer cells, reduces FB1 (Fumonisin B1) (HY-N6719)-induced autophagy and cell death, regulates PGG-induced senescence and apoptosis, and alleviates Sorafenib (HY-10201)-induced vacuolization and damage in hepatic stellate cells. 3-Ethoxy-5,6-dibromosalicylaldehyde can be used in research related to chikungunya virus infection, pancreatic cancer, FB1-induced nephrotoxicity, liver cancer, breast cancer, lung cancer and liver fibrosis .
loading...
    loading...